University of California, Los Angeles

The biopharmaceutical industry has been through a tremendous period of company creation, and even with a drop in financings during 2022 and 2023 from record levels of funding in 2020 and 2021, the las

Venture capital firms that support biotechnology companies are raising billions of dollars to make new investments in 2023, but so far this year VC investors have invested conservatively in drug devel

ImmPACT Bio USA emerged from the FutuRx incubator in Israel in 2017 to develop chimeric antigen receptor T-cell (CAR-T) therapies that could be effective against solid tumors. Now, with $111m in seri

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Seagen, RemeGen Partner Outside Asia, E